Debiopharm extends their DNA damage repair footprint With new oncology pipeline entry
Debiopharm obtains global rights from Novo Nordisk for the development of their ubiquitin-specific protease 1 (USP1) inhibitor.
- 02.03.2023, 09:00
- Kategoria: Nauka i technologie
- Źródło: APA-OTS